Prostate cancer genome viewed with powerful technique
Prostate cancer research using whole genome sequencing analysis may lead to the identification of novel therapeutic targets as well as diagnostic tools for identifying aggressive primary tumors and characterizing genomic changes associated with disease progression.
New York-Prostate cancer research using whole genome sequencing analysis may lead to the identification of novel therapeutic targets as well as diagnostic tools for identifying aggressive primary tumors and characterizing genomic changes associated with disease progression.
To characterize prostate cancer genomic alterations, parallel sequencing of the entire genome was performed using normal tissue and tumor specimens from seven men with high-risk primary prostate cancer who underwent robotic radical prostatectomy performed by Ashutosh Tewari, MD, of Weill Cornell Medical College.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.
